fda ruling on tirzepatide update Is Legal in 2026? Status, Compounding Ban & FDA says compounding pharmacies can

Cardiovascular Evidence# LEADER Trial (Liraglutide)# The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 patients with T2D and high CV risk, followed for median 3.8 years: 3-point MACE: HR 0.87 (95% CI 0.78-0.97, p=0.01) -- 13% reduction Cardiovascular death: HR 0.78 (22% reduction) All-cause mortality: HR 0.85 (15% reduction) Liraglutide was the first GLP-1 agonist to demonstrate cardiovascular benefit, and LEADER remains a landmark trial in the class

Drinking adequate water, limiting alcohol (which impairs satiety signals), and tracking your intake without obsession create the ideal environment for steady, predictable weight loss

You can also see if you qualify for Noom Med

Contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Efficacy and safety of tirzepatide versus semaglutide once weekly as addon therapy to metformin in people with type 2 diabetes (SURPASS2)

Starting probiotics two to four weeks before your first semaglutide injection allows beneficial bacteria to establish populations before the medication disrupts the gut microbiome